Extended Data Fig. 10: sAXL levels and proangiogenic CHSPCs vs clinical response to cabozantinib in trial participants.
From: Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial
a, A panel of 45 cytokines including soluble AXL (sAXL) were analyzed in the serum of clinical trial participants (n = 6 with SD, n = 8 with PR). The barplot depicts the change in the mean level of sAXL (ng/mL) between baseline/early (C0/C15) and later cycles (C2/C4) by clinical response of study participants (SD vs PR; P = 0.08 by two-tailed, Mann-Whitney test). Grubb’s test with an alpha value of 0.05 did not identify any statistical outliers within the dataset. Whiskers extend from the minima to maxima. The center line represents the median. The box spans the 25th to 75th percentiles. b, The frequency of proangiogenic CHSPCs was analyzed in the peripheral blood in n = 13 participants (n = 6 with SD, and n = 7 with PR) collected at 4 time points: prior to cycle 1/baseline (C0), cycle 1 day 15 (C1D15) end of cycle 2 (C2), and end of cycle 4 (C4). The change in the mean frequency of proangiogenic CHSPCs from early (C0/C1D15) to later (C2/C4) treatment cycles was plotted in participants with SD vs PR (p = 0.6282 by two-tailed, Mann Whitney test). Whiskers extend from the minima to maxima. The center line represents the median. The box spans the 25th to 75th percentiles. c, Gating strategy for identification of proangiogenic CHSPCs by flow cytometry.
